Spotlight on JLABS

Oct 13 2016

Come one, come all! You are invited to learn more about some of the exciting companies creating scientific breakthroughs at JLABS in Houston. JLABS @ TMC currently holds over 20 companies and has several more in the pipeline. Four companies will give candid, informative presentations detailing their executive teams, an overview of their company and highlighting their reasons for joining JLABS. Don't miss this opportunity to learn more about the progress of this exciting project and meet the companies within JLABS. Please note that the presentations at this event will include publicly available, non-confidential information only.

Thursday, October 13, 2016

3:00 PM | Registration Opens & Overview
3:30 PM | Presentations
4:45 PM | Networking Reception
6:00 PM | Program Close

Presenting Companies:
Beta Cat Pharmaceuticals read more»
CorInnova read more»
Immunophotonics read more»
Oncomfort read more»

Please RSVP online so that we can get an accurate headcount for food and beverages. 

John P. McGovern Campus
2450 Holcombe Blvd, Suite J
Houston, TX 77021

Presenting Companies' Descriptions:

Beta Cat Pharmaceuticals
Beta Cat is an emerging growth biotechnology company developing novel treatments for cancer. Beta Cat's lead compound, Tegatrabetan (BC2059) is a unique therapeutic, inhibiting a very important embryonic stem cell pathway (WNT/ beta catenin) cancer uses to become "stem-cell like". This is an escape/resistance pathway to many of the most effective cancer therapeutics utilized in medical practice today (i.e. immune-oncology agents, targeted agents, and chemotherapy standards of care). While the greatest potential for Tegatrabetan is in combination with other cancer therapies across a wide range of solid and hematological cancers, there are also several single agent, accelerated approval possibilities for fast marketing of the drug. Tegatrabetan should be the answer for desmoid tumors, an invasive and potentially deadly orphan cancer, and in germinal center B cell lymphomas, where the drug has exhibited extremely potent activity in pre-clinical studies. Tegatrabetan in combination studies, also has the potential for orphan disease status and accelerated approval in a deadly form of leukemia, AML.

With a $6 million lead investment from a major international foundation, CorInnova is developing a non-blood contacting biventricular cardiac assist device to treat end stage heart failure to the point of first-in-human clinical results. The device would be much safer than existing left ventricular assist devices (LVADs). The device could eliminate 40% of adverse events associated with LVADs and expand the eligible patient population by 3 to 4 times. The addressable market would be as large as $14 billion. CorInnova's device would create a new paradigm for the treatment of heart failure. Similar companies have sold for up to $850 million, and 3 cardiac companies with data in 10 patients or less sold for $250 to $400 million in cash in 2015. Several major medical device companies have indicated a significant interest in partnering once first-in-human is achieved. The latest version of the device fits into a one inch delivery tube, deploys into the pericardial sac in under 15 seconds and has shown the ability to increase cardiac output by 50 to 90% in acute large animal studies. CorInnova has built a world-class team to take advantage of the opportunity.


Immunophotonics, Inc. is a biotech company developing a proprietary drug for use in a therapeutic cancer vaccine (inCVAX) for the potential treatment of solid, metastatic tumors. While additional clinical trials are necessary to further assess safety and efficacy, first-in-human results of inCVAX have been encouraging. inCVAX belongs to a new class of therapeutic interventions that utilize intratumoral injections intended to elicit a systemic anti-tumor immune response against a cancer. The inCVAX two-step procedure involves: 1) priming a tumor with laser energy to liberate an array of tumor antigens from whole cells, followed by 2) administration of GC, a proprietary semi-synthetic carbohydrate polymer designed to activate antigen-presenting cells and facilitate the uptake of tumor antigens, which in turn is intended to trigger a systemic anti-tumor immune response. Extensive nonclinical research is being performed to enable submission of IND (US) and CTA (Europe) applications. In parallel, a randomized controlled trial on advanced breast cancer is being conducted in South America (SA) in partnership with a local pharma company (open IND, trial initiated Q3 2016).

Oncomfort offers the world's first library of stress management modules combining evidence-based psychological interventions with Virtual Reality.  Our modules are non-pharmacological, non-invasive, safe and easy to use.  Patients feel more comfortable and empowered.  Through our immersive modules, patients receive standardized information on the procedure, surgery or treatment.  They are also trained in evidence-based stress management techniques.